With a revenue increase of 567.5% in the second quarter 2026, year on year to cumulative value of $7 million, Allogene Therapeutics Inc 's revenue per employee grew on a trailing twelve months basis to $ 45,000. The productivity of Allogene Therapeutics Inc 's employees was 0.0%, above the company average. Within the Healthcare sector Allogene Therapeutics Inc achieved the highest revenue per employee. While revenue per employee remained unchanged compared to the previous quarter at no. .Allogene Therapeutics Inc has 152 employees.
Allogene Therapeutics Faces a Pivotal Moment Following the Passing of Founding Board Member David Bonderman SOUTH SAN FRANCISCO, Calif. Dec. 12, 2024 — In the corridors of Allogene Therapeutics, Inc. the news of David Bonderman s passing reverberates deeply. A founding board member and influential figure in the biotechnology sector, Bonderman succumbed to age-related health issues at the age of 82, surrounded by his family. While his legacy as a visionary leader and financier is well-established, the future of Allogene Therapeutics now hangs in a delicate balance as the company grapples with financial struggles alongside significant potential in the biopharmaceutical landscape.Allogene Therapeutics, specializing in pioneering allogeneic CAR T (AlloCAR T) therapies designed for cancer and autoimmune diseases, faces the challenge of maintaining momentum and support for innovative therapies during a difficult financial period. The company reported a cumulative net loss of $0 million for the twelve months ending September 30, 2024, raising concerns from stakeholders about the sustainability of its ambitious projects. Despite these financial headwinds, Allogene Therapeutics has achieved remarkable productivity within the healthcare sector, boasting the highest revenue per employee among its peers. With a current workforce of 300, this statistic suggests that the company’s efforts to streamline its operations and maximize output have garnered some success. However, the fundamental question remains: can innovation be sustained amid significant losses?Recent developments, including Allogene s presentation of groundbreaking CAR T data at leading conferences such as the American College of Rheumatology (ACR) and the Society for Immunotherapy of Cancer (SITC), signal a glimmer of hope. The company unveiled pivotal data on promising investigational therapies, specifically ALLO-329 and ALLO-316, designed to tackle autoimmune diseases and advanced renal cell carcinoma (RCC) respectively. ALLO-329 stands out due to its innovative dual CAR T approach, simultaneously targeting CD19 and CD70. This groundbreaking method not only enhances the therapeutic capabilities of CAR T therapy but also potentially addresses a broader range of immune response modulation. Given that autoimmune diseases impact millions worldwide, the implications of such advancements could be transformative, not just for Allogene Therapeutics but for the entire therapeutic landscape.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
